AnaptysBio (NASDAQ:ANAB) Given “Outperform” Rating at Wedbush

Wedbush reiterated their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report released on Monday morning,RTT News reports. Wedbush currently has a $40.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on the stock. Wells Fargo & Company lowered their price target on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Guggenheim cut their price target on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Truist Financial cut their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.45.

AnaptysBio Trading Down 7.1 %

ANAB opened at $16.66 on Monday. The stock has a market capitalization of $506.96 million and a PE ratio of -2.74. AnaptysBio has a 1-year low of $12.51 and a 1-year high of $41.31. The firm has a 50-day moving average price of $17.38 and a two-hundred day moving average price of $27.01.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, research analysts predict that AnaptysBio will post -6.08 EPS for the current year.

Insider Transactions at AnaptysBio

In related news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after buying an additional 438,557 shares during the period. Jennison Associates LLC acquired a new stake in AnaptysBio during the 3rd quarter valued at approximately $8,874,000. Victory Capital Management Inc. raised its holdings in AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of AnaptysBio in the 3rd quarter valued at $5,494,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.